Monday, August 09, 2021 11:58:13 PM
Thanks for the shout-out BBNCT. Yes, the situation there seems to be growing more dire by the day. Communication with my contacts in the medical field have been much less frequent since the FDA letter (unsurprisingly) and like-wise; I have not tried to rock the boat.
As of June, there was still plenty of leronlimab dispersed throughout the hospitals and doctors would treat any severe or critical patient who could prove they have the means to pay for the drug. I'll repeat the info here from my last post that details a recent successfully treated case in June from my last correspondance:
A younger person in their 20's suffered with a severe case of COVID and overwhelming cytokine storm reaction at home for 3 weeks before being hospitalized with hypoxemia. At hospitalization, their blood oxygen levels were as low as 72-73.
The patient was given oxygen support and 3 doses of Leronlimab. Dramatic improvement was seen on week 1 with oxygen levels back in the low 90s and sustainable improvement in recovery was observed in the following 2 weeks of treatment. They were kept in the hospital for an additional week for observation and later released after 4 weeks total in the hospital. Blood work was also taken for bio-marker analysis during treatment periods.
The drug works without a doubt. I'll reach out again and see what falls from the tree over the next couple of days.
As of June, there was still plenty of leronlimab dispersed throughout the hospitals and doctors would treat any severe or critical patient who could prove they have the means to pay for the drug. I'll repeat the info here from my last post that details a recent successfully treated case in June from my last correspondance:
A younger person in their 20's suffered with a severe case of COVID and overwhelming cytokine storm reaction at home for 3 weeks before being hospitalized with hypoxemia. At hospitalization, their blood oxygen levels were as low as 72-73.
The patient was given oxygen support and 3 doses of Leronlimab. Dramatic improvement was seen on week 1 with oxygen levels back in the low 90s and sustainable improvement in recovery was observed in the following 2 weeks of treatment. They were kept in the hospital for an additional week for observation and later released after 4 weeks total in the hospital. Blood work was also taken for bio-marker analysis during treatment periods.
The drug works without a doubt. I'll reach out again and see what falls from the tree over the next couple of days.
Recent CYDY News
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
